July 30, 2025

Seed raise exceeding 200% of target positions the DebitMyData Digital Identity LLM (DID-LLM) for Global Partnerships and Licensing DebitMyData Logo FORT LAUDERDALE, Fla., July 30, 2025 (GLOBE NEWSWIRE) — DebitMyData, Inc.—the powerhouse has closed a seed round at more than twice its original target. This surge of investor confidence paves the way for a bold, billion-dollar global rollout of DebitMyData’s Human Energy Grid, setting a new standard for individual data ownership, ethical monetization, and human-centric AI innovation. Preparing to launch a U.S and global expansion round, DebitMyData is already attracting top-tier venture capitalists—some of whom previously backed OpenAI alumni Ilya

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis  Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, Allianthera (Suzhou) Biopharmaceuticals Co., Ltd., and its affiliate Allianthera Boston, Inc., a clinical stage biotechnology company focusing on novel drug research and development in immunology and inflammatory diseases, (Allianthera), are pleased to announce the signing of an agreement on the co-development, license option, manufacturing, and commercialization of the novel

Ambiq Announces Pricing of Initial Public Offering Ambiq Announces Pricing of Initial Public Offering AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) — Ambiq Micro, Inc. (“Ambiq”), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced the pricing of its upsized initial public offering of 4,000,000 shares of its common stock at a public offering price of $24.00 per share. The gross proceeds to Ambiq from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Ambiq, are expected to be $96.0 million. In addition, Ambiq has granted the underwriters a 30-day option to

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), July 29, 2025, 10:45 pm CET / 4:45 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,432,066.28 Total number of securities carrying voting rights: 37,441,140 (all ordinary shares) Total number of voting rights (= denominator): 37,441,140 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 2,793,941 (all granted subscription rights; this number

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s